Heo, Young-A
Published in
BioDrugs
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. GP2017 has similar physicochemical and functional properties to those of reference adalimumab, and the pharmacokinetic similarity of the agent has been shown in healthy male volunteers. GP2017 demo...
Al-Salama, Zaina T.
Published in
BioDrugs
The article PF-06438179/GP1111: An Infliximab Biosimilar, written by Zaina T. Al-Salama
Mahlangu, Johnny N.
Published in
BioDrugs
Current unmet needs in haemophilia A patients with inhibitors include the need for intravenous infusion of replacement therapy and the high burden of treatment associated with prophylaxis. Emicizumab is a humanised bispecific monoclonal antibody designed to address these unmet needs and has completed phase III clinical trials in adolescents/adults ...
Kim, Su Jung Lee, Joon Won Kang, Hye Young Kim, So Young Shin, Yeon Kyeong Kim, Kwang Woo Oh, Jun Seok Lim, Ki Jung Kim, Ji Young
Published in
BioDrugs
BackgroundCT-P6 is a biosimilar of trastuzumab, a monoclonal antibody targeting human epidermal growth factor 2 (HER2), that is used in the treatment of breast and gastric cancers.ObjectiveThe aim of this study was to evaluate the in-use physicochemical and biological stability of CT-P6 following preparation for intravenous (IV) infusion.MethodsOne...
Scavone, Cristina Sessa, Maurizio Clementi, Emilio Corrao, Giovanni Leone, Roberto Mugelli, Alessandro Rossi, Francesco Spina, Edoardo Capuano, Annalisa
Published in
BioDrugs
BackgroundIn recent years, several biosimilar drugs, including those of infliximab, have obtained marketing authorization from the European Medicines Agency (EMA). Given the peculiarity of the safety profile of biological medical products (originator and biosimilars), the evaluation of their tolerability represents an important component of pre-mar...
Scott, Lesley J.
Published in
BioDrugs
Darvadstrocel (Alofisel®) consists of a suspension of expanded human allogeneic adipose-derived mesenchymal stem cells (eASCs). It is the first mesenchymal stem cell (MSC) advanced therapy approved in the EU for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have sho...
Paik, Julia
Published in
BioDrugs
PF-05280014 (Trazimera™) is the fourth biosimilar of the reference anti-HER2 antibody trastuzumab to be approved in the EU. It is approved for use in all indications for which reference trastuzumab is approved, including HER2-positive metastatic or early breast cancer and metastatic gastric cancer. PF-05280014 has similar physicochemical and pharma...
Khera, Eshita Thurber, Greg M.
Published in
BioDrugs
Antibody–drug conjugate (ADC) development has evolved greatly over the last 3 decades, including the Food and Drug Administration (FDA) approval of several new drugs. However, translating ADCs from the design stage and preclinical promise to clinical success has been a major hurdle for the field, particularly for solid tumors. The challenge in clin...
Deeks, Emma D.
Published in
BioDrugs
The article GP2015: An Etanercept Biosimilar, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 31, issue 6, pages 555–558 HEXAL AG requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by HEXAL AG. The article ...
Husain, Bushra Ellerman, Diego
Published in
BioDrugs
Bispecific antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra® and Blincyto®) and many more in clinical trials. The success of bispecific antibodies is mainly due to the continuously growing number of mechanisms of actions (MOA) they enable that are...